doi: 10.1042/BSR20180411.
Print 2018 Oct 31.
The N-terminal polypeptide derived from vMIP-II exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1
Affiliations
- PMID: 30104400
- PMCID: PMC6200706
- DOI: 10.1042/BSR20180411
Item in Clipboard
The N-terminal polypeptide derived from vMIP-II exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1
Biosci Rep.
.
Abstract
Accumulating evidence demonstrates that long non-coding RNA (lncRNA) sprouty4-intron transcript 1 (lncRNA SPRY4-IT1) plays a vital role in the development of breast cancer. However, the underlying mechanism has not been eventually illuminated. We aimed to explore the biological activity of lncRNA SPRY4-IT1 in breast cancer cells and whether N-terminal polypeptide derived from viral macrophage inflammatory protein II (NT21MP) could exert its anti-tumor effect by regulating lncRNA SPRY4-IT1 and its target gene SKA2 Real-time RT-PCR, Western blotting, wound healing, and invasion assays were used to achieve this goal. We found that lncRNA SPRY4-IT1 was highly expressed in breast cancer cells. Moreover, NT21MP markedly inhibited biological effects of breast cancer cells by regulating lncRNA SPRY4-IT1, which was partially achieved through SKA2. Our findings suggested that lncRNA SPRY4-IT1 could serve as a novel biomarker by NT21MP for breast cancer.
Keywords: Breast cancer; NT21MP; SKA2; SPRY4-IT1.
© 2018 The Author(s).
Conflict of interest statement
The authors declare that there are no competing interests associated with the manuscript.
Figures
(A) The effects of depletion or overexpression of CXCR4 on the expression of SPRY4-IT1. (B) The influences of NT21MP on the expression of SPRY4-IT1. Data were presented as mean ± S.D. of three independent experiments. **P<0.05; #P or ##P<0.05. ns represents P>0.05 compared with the control group.
(A) The mRNA level of SPRY4-IT1 in breast cancer cell lines (MCF-7, pC-MDA-MB-231, and SKBR-3) was compared with human breast epithelial cells (MCF-10A). (B) Quantitative RT-PCR screened the best siRNAs of SPRY4-IT1 after transfection of SPRY4-IT1. (C) Quantitative RT-PCR screened the cell lines of overexpression of the SPRY4-IT1. The data are the result of three independent experiments and are presented as mean ± S.D.; **P<0.05; ***P<0.01. ‘PC-MDA-MB-231’ is short for ‘pcDNA-CXCR4-MDA-MB-231’, ‘SS’ is short for ‘si-SPRY4-IT1’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1’.
(A) The influence of depletion or overexpression of SPRY4-IT1 on cell proliferation in pcDNA-CXCR4-MDA-MB-231 cells and MCF-7 cells was measured by SRB assays. (B) Representative images indicated the invading cells with down-regulated or up-regulated SPRY4-IT1 analyzed by Transwell assay. Scale bar: 50 μm. Data are mean ± S.D. of five fields. (C) Quantitative results are illustrated for (B). (D) The influence of depletion or overexpression of SPRY4-IT1 on cell migration in breast cancer cells was measured by wound healing assays. (E) Effects of SPRY4-IT1 on cell cycle in breast cancer cells. The influence of depletion or overexpression of SPRY4-IT1 on cell cycle was analyzed by propidium iodide staining and flow cytometry. Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with down-regulated or up-regulated SPRY4-IT1. (F) Quantitative results are illustrated for (E). (G) Effects of SPRY4-IT1 on apoptosis in breast cancer cells. The influence of depletion or overexpression of SPRY4-IT1 on cell apoptosis was evaluated by AnnexinV/PI staining and flow cytometry. (H) Bar plots illustrate the percentage of apoptosis cells in breast cancer cells with down-regulated or up-regulated SPRY4-IT1. (I) Effects of SPRY4-IT1 on cell cycle and apoptosis related factors in breast cancer cells. The influence of depletion or overexpression of SPRY4-IT1 on the mRNA level of cell cycle and apoptosis related factors was analyzed by qRT-PCR. (J) Western blot analyzed the protein level of cell cycle and apoptosis related factors in breast cancer cells with down-regulated or up-regulated SPRY4-IT1. Data were presented as mean ± S.D. of three independent experiments. *P or **P<0.05, ***P<0.01. ##P<0.05 or ###P<0.01 vs control group. ‘SS’ is short for ‘si-SPRY4-IT1-3’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1-3’.
(A) The influence of depletion or overexpression of SPRY4-IT1 on cell proliferation in pcDNA-CXCR4-MDA-MB-231 cells and MCF-7 cells was measured by SRB assays. (B) Representative images indicated the invading cells with down-regulated or up-regulated SPRY4-IT1 analyzed by Transwell assay. Scale bar: 50 μm. Data are mean ± S.D. of five fields. (C) Quantitative results are illustrated for (B). (D) The influence of depletion or overexpression of SPRY4-IT1 on cell migration in breast cancer cells was measured by wound healing assays. (E) Effects of SPRY4-IT1 on cell cycle in breast cancer cells. The influence of depletion or overexpression of SPRY4-IT1 on cell cycle was analyzed by propidium iodide staining and flow cytometry. Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with down-regulated or up-regulated SPRY4-IT1. (F) Quantitative results are illustrated for (E). (G) Effects of SPRY4-IT1 on apoptosis in breast cancer cells. The influence of depletion or overexpression of SPRY4-IT1 on cell apoptosis was evaluated by AnnexinV/PI staining and flow cytometry. (H) Bar plots illustrate the percentage of apoptosis cells in breast cancer cells with down-regulated or up-regulated SPRY4-IT1. (I) Effects of SPRY4-IT1 on cell cycle and apoptosis related factors in breast cancer cells. The influence of depletion or overexpression of SPRY4-IT1 on the mRNA level of cell cycle and apoptosis related factors was analyzed by qRT-PCR. (J) Western blot analyzed the protein level of cell cycle and apoptosis related factors in breast cancer cells with down-regulated or up-regulated SPRY4-IT1. Data were presented as mean ± S.D. of three independent experiments. *P or **P<0.05, ***P<0.01. ##P<0.05 or ###P<0.01 vs control group. ‘SS’ is short for ‘si-SPRY4-IT1-3’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1-3’.
(A) Effects of NT21MP and depletion or overexpression of SPRY4-IT1 on cell proliferation in breast cancer cells. The cells were transfected with SPRY4-IT1-specific siRNA or SPRY4-IT1-specific pcDNA-vector and stimulated with (+SDF-1α) or not (−SDF-1α) with 100 ng/ml of SDF-1α and NT21MP (1.0 μg/ml). (B) Representative images indicated the invading cells with down-regulated or up-regulated SPRY4-IT1 combinded with NT21MP analyzed by Transwell assay; scale bar: 50 μm. (C) Quantitative results are illustrated for (B). (D) The influence of NT21MP and depletion or overexpression of SPRY4-IT1 on cell migration and invasion were measured by wound healing assays. (E) Effects of NT21MP and depletion or overexpression of SPRY4-IT1 on cell cycle in breast cancer cells. The cells were transfected with SPRY4-IT1-specific siRNA or SPRY4-IT1-specific pcDNA-vertor and stimulated with (+SDF-1α) or not (−SDF-1α) with 100 ng/ml of SDF-1α and NT21MP (1.0 μg/ml). The influence of NT21MP and depletion or overexpression of SPRY4-IT1 on cell cycle were analyzed by propidium iodide staining and flow cytometry. Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with down-regulated or up-regulated SPRY4-IT1 combined with NT21MP. (F) Quantitative results are illustrated for (E). (G) Effects of NT21MP and depletion or overexpression of SPRY4-IT1 on apoptosis in breast cancer cells. The influence of NT21MP and depletion or overexpression of SPRY4-IT1 on cell apoptosis were evaluated by AnnexinV/PI staining and flow cytometry. Bar plots illustrating the percentage of apoptosis cells in breast cancer cells with down-regulated or up-regulated SPRY4-IT1 combined with NT21MP. (H) Quantitative results are illustrated for (G). Data were presented as mean ± S.D. of five fields, *P or **P<0.05; ***P<0.01; #P or ##P<0.05; ###P<0.01; @P or @@P<0.05; @@@P<0.01; ΔP or ΔΔP<0.05; ΔΔΔP<0.01. ‘SS’ is short for ‘si-SPRY4-IT1-3’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1-3’.
(A) Effects of NT21MP and depletion or overexpression of SPRY4-IT1 on cell proliferation in breast cancer cells. The cells were transfected with SPRY4-IT1-specific siRNA or SPRY4-IT1-specific pcDNA-vector and stimulated with (+SDF-1α) or not (−SDF-1α) with 100 ng/ml of SDF-1α and NT21MP (1.0 μg/ml). (B) Representative images indicated the invading cells with down-regulated or up-regulated SPRY4-IT1 combinded with NT21MP analyzed by Transwell assay; scale bar: 50 μm. (C) Quantitative results are illustrated for (B). (D) The influence of NT21MP and depletion or overexpression of SPRY4-IT1 on cell migration and invasion were measured by wound healing assays. (E) Effects of NT21MP and depletion or overexpression of SPRY4-IT1 on cell cycle in breast cancer cells. The cells were transfected with SPRY4-IT1-specific siRNA or SPRY4-IT1-specific pcDNA-vertor and stimulated with (+SDF-1α) or not (−SDF-1α) with 100 ng/ml of SDF-1α and NT21MP (1.0 μg/ml). The influence of NT21MP and depletion or overexpression of SPRY4-IT1 on cell cycle were analyzed by propidium iodide staining and flow cytometry. Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with down-regulated or up-regulated SPRY4-IT1 combined with NT21MP. (F) Quantitative results are illustrated for (E). (G) Effects of NT21MP and depletion or overexpression of SPRY4-IT1 on apoptosis in breast cancer cells. The influence of NT21MP and depletion or overexpression of SPRY4-IT1 on cell apoptosis were evaluated by AnnexinV/PI staining and flow cytometry. Bar plots illustrating the percentage of apoptosis cells in breast cancer cells with down-regulated or up-regulated SPRY4-IT1 combined with NT21MP. (H) Quantitative results are illustrated for (G). Data were presented as mean ± S.D. of five fields, *P or **P<0.05; ***P<0.01; #P or ##P<0.05; ###P<0.01; @P or @@P<0.05; @@@P<0.01; ΔP or ΔΔP<0.05; ΔΔΔP<0.01. ‘SS’ is short for ‘si-SPRY4-IT1-3’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1-3’.
The influence of depletion (A,B) or overexpression (C,D) of SPRY4-IT1 on the expression of SKA2 in breast cancer cells by quantitative RT-PCR and protein level. Data were presented as mean ± S.D. of three independent experiments, *P or **P<0.05. ‘SS’ is short for ‘si-SPRY4-IT1-3’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1-3’.
(A) The mRNA and protein level of SKA2 in the MCF-7, pC-MDA-MB-231, and SKBR-3 cells. (B) The protein level of SKA2 in the MCF-7, pC-MDA-MB-231, and SKBR-3 cells. (C) Quantitative RT-PCR screened the best siRNAs of SKA2 after transfection of SKA2-specific siRNA or a non-targetting control siRNA for 24 h. (D) Western blot screened the best siRNAs of SKA2 after transfection with SKA2-specific siRNA or a non-targetting control siRNA for 24 h. Data were presented as mean ± S.D. of three independent experiments, ***P<0.01.
(A) The influence of depletion of SKA2 on the ability of cell proliferation in breast cancer cells. (B) Representative images indicated that the invading cells with down-regulated SKA2 analyzed by Transwell assays; scale bar: 50 μm. (C) Quantitative results are illustrated for (B). (D) The influence of depletion of SKA2 on cell migration and invasion was measured by wound healing assays. (E) The influence of depletion of SKA2 on the cell cycle in breast cancer cells. The influence of depletion of SKA2 on cell cycle was analyzed by propidium iodide staining and flow cytometry. Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with depletion of SKA2. (F) Quantitative results are illustrated for (E). (G) The influence of depletion of SKA2 on apoptosis in breast cancer cells. The influence of depletion of SKA2 on cell apoptosis was evaluated by AnnexinV/PI staining and flow cytometry. (H) Bar plots illustrating the percentage of apoptosis cells in breast cancer cells with depletion of SKA2. (I) Effects of depletion of SKA2 on cell cycle and apoptosis related factors in breast cancer cells. The influence of depletion of SKA2 on the mRNA level of cell cycle and apoptosis-related factors were analyzed by qRT-PCR. (J) Western blot analyzed the protein level of cell cycle and apoptosis-related factors in breast cancer cells with depletion of SKA2. The data are the results of three independent experiments and are presented as mean ± S.D. *P and ##P<0.05; **P<0.05 or ***P<0.01. ‘si-SKA2’ is short for ‘si-SKA2-1’.
(A) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell proliferation in breast cancer cells. (B) Representative images indicated that the invading cells with depletion of SKA2 and depletion or overexpression of SPRY4-IT1 analyzed by Transwell assay; scale bar: 50 μm. (C) Quantitative results are illustrated for (B). (D) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell migration and invasion in breast cancer cells were measured by wound healing assays. (E) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell cycle in breast cancer cells. The influence of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell cycle were analyzed by propidium iodide staining and flow cytometry. (F) Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with depletion of SKA2 and depletion or overexpression of SPRY4-IT1. (G) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on apoptosis in breast cancer cells. The influence of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell apoptosis were evaluated by Annexin V/PI staining and flow cytometry. (H) Bar plots illustrating the percentage of apoptosis cells in breast cancer cells with depletion of SKA2 and depletion or overexpression of SPRY4-IT1. Data were presented as mean ± S.D. of three independent experiments, **P<0.05, ***P<0.01, #P or ##P<0.05, ###P<0.01. *P<0.05; @P or @@P<0.05; @@@P<0.01; ΔP or ΔΔP<0.05,ΔΔΔ; P<0.01. ‘SS’ is short for ‘si-SPRY4-IT1-3’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1-3’, ‘si-SKA2’ is short for ‘si-SKA2-1’.
(A) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell proliferation in breast cancer cells. (B) Representative images indicated that the invading cells with depletion of SKA2 and depletion or overexpression of SPRY4-IT1 analyzed by Transwell assay; scale bar: 50 μm. (C) Quantitative results are illustrated for (B). (D) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell migration and invasion in breast cancer cells were measured by wound healing assays. (E) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell cycle in breast cancer cells. The influence of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell cycle were analyzed by propidium iodide staining and flow cytometry. (F) Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with depletion of SKA2 and depletion or overexpression of SPRY4-IT1. (G) Effects of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on apoptosis in breast cancer cells. The influence of depletion of SKA2 and depletion or overexpression of SPRY4-IT1 on cell apoptosis were evaluated by Annexin V/PI staining and flow cytometry. (H) Bar plots illustrating the percentage of apoptosis cells in breast cancer cells with depletion of SKA2 and depletion or overexpression of SPRY4-IT1. Data were presented as mean ± S.D. of three independent experiments, **P<0.05, ***P<0.01, #P or ##P<0.05, ###P<0.01. *P<0.05; @P or @@P<0.05; @@@P<0.01; ΔP or ΔΔP<0.05,ΔΔΔ; P<0.01. ‘SS’ is short for ‘si-SPRY4-IT1-3’, ‘PS’ is short for ‘pcDNA-SPRY4-IT1-3’, ‘si-SKA2’ is short for ‘si-SKA2-1’.
(A) Effects of NT21MP and depletion of SKA2 on the ability of cell proliferation in breast cancer cells. The cells were transfected with SKA2-specific siRNA and stimulated with (+SDF-1α) or not (−SDF-1α) with 100 ng/ml of SDF-1α and NT21MP (1.0 μg/ml). (B) The influence of NT21MP and depletion of SKA2 on cell migration and invasion were measured by Transwell assays. Representative images indicated that the invading cells with depletion of SKA2 combined with NT21MP analyzed by Transwell assay; scale bar: 50 μm. (C) Quantitative results are illustrated for (B). (D) The influence of NT21MP and depletion of SKA2 on cell migration and invasion were measured by wound healing assays. (E) Effects of NT21MP and depletion of SKA2 on cell cycle in breast cancer cells. The cells were transfected with SKA2-specific siRNA and stimulated with (+SDF-1α) or not (−SDF-1α) with 100 ng/ml of SDF-1α and NT21MP (1.0 μg/ml). The influence of NT21MP and depletion of SKA2 on cell cycle were analyzed by propidium iodide staining and flow cytometry. (F) Effects of NT21MP and depletion of SKA2 on apoptosis in breast cancer cells. The influence of NT21MP and depletion of SKA2 on cell apoptosis were evaluated by AnnexinV/PI staining and flow cytometry. (G) Bar plots illustrating the percentage of G0/G1 and S phase in breast cancer cells with depletion of SKA2 combined with NT21MP. (H) Bar plots illustrating the percentage of apoptosis cells in breast cancer cells with depletion of SKA2 combined with NT21MP. Data were presented as mean ± S.D. of three independent experiments. *P or **P<0.05; #P or ##P<0.05, ###P<0.01; @P or @@P<0.05, @@@P<0.01; △P or △△P<0.05, △△△P<0.01. ‘si-SKA2’ is short for ‘si-SKA2-1’.
Similar articles
-
Long non-coding RNA SPRY4-IT1 promotes epithelial-mesenchymal transition of cervical cancer by regulating the miR-101-3p/ZEB1 axis.Biosci Rep. 2019 Jun 4;39(6):BSR20181339. doi: 10.1042/BSR20181339. Print 2019 Jun 28. Biosci Rep. 2019. PMID: 31092700 Free PMC article.
-
Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.Biomed Pharmacother. 2017 Jan;85:348-354. doi: 10.1016/j.biopha.2016.11.035. Epub 2016 Nov 28. Biomed Pharmacother. 2017. PMID: 27899259
-
EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.Cell Death Dis. 2014 Jun 26;5(6):e1298. doi: 10.1038/cddis.2014.256. Cell Death Dis. 2014. PMID: 24967960 Free PMC article. Clinical Trial.
-
The long non-coding RNA SPRY4-IT1: An emerging player in tumorigenesis and osteosarcoma.Cell Prolif. 2018 Aug;51(4):e12446. doi: 10.1111/cpr.12446. Epub 2018 Feb 27. Cell Prolif. 2018. PMID: 29484753 Free PMC article. Review.
-
Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database.Biomed Res Int. 2020 Nov 1;2020:5868602. doi: 10.1155/2020/5868602. eCollection 2020. Biomed Res Int. 2020. PMID: 33204703 Free PMC article.
Cited by
-
LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.J Cell Mol Med. 2020 Jan;24(1):772-784. doi: 10.1111/jcmm.14786. Epub 2019 Nov 17. J Cell Mol Med. 2020. PMID: 31736268 Free PMC article.
-
Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.Heliyon. 2024 Jul 26;10(15):e35208. doi: 10.1016/j.heliyon.2024.e35208. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170516 Free PMC article. Review.
-
Metformin and long non-coding RNAs in breast cancer.J Transl Med. 2023 Feb 27;21(1):155. doi: 10.1186/s12967-023-03909-x. J Transl Med. 2023. PMID: 36849958 Free PMC article. Review.
-
Upregulation of microRNA-520a-3p inhibits the proliferation, migration and invasion via spindle and kinetochore associated 2 in gastric cancer.Oncol Lett. 2019 Sep;18(3):3323-3330. doi: 10.3892/ol.2019.10663. Epub 2019 Jul 25. Oncol Lett. 2019. PMID: 31452811 Free PMC article.
-
A Review on the Role of SPRY4-IT1 in the Carcinogenesis.Front Oncol. 2022 Jan 13;11:779483. doi: 10.3389/fonc.2021.779483. eCollection 2021. Front Oncol. 2022. PMID: 35096580 Free PMC article. Review.
References
-
- Donepudi M.S., Kondapalli K., Amos S.J. and Venkanteshan P. (2014) Breast cancer statistics and markers. J. Cancer Res. Ther. 10, 506–511 - PubMed
-
- Lei H. Gao Y. and Xu X. (2017) LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim. Biophys. Sin. 22, 1–10 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
